Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Eve vs Signos

Eve
Graded #212

Higher grade

vs+4.600000000000001
Signos
Graded #295

Lower grade

The verdict

Eve takes it — 66/100 to 61.4/100.

Eve grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eve is a women's-health-focused GLP-1 telehealth platform — distinctive positioning in a largely gender-neutral market — offering both compounded semaglutide and tirzepatide (including an oral sublingual…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEve +10
54
44
Dose & formulationEve +24
88
64
Clinical oversightSignos +5
79
84
Labs & monitoringSignos +19
52
71
FulfillmentSignos +4
67
71
Contract termsEve +21
41
20
Eve · left barSignos · right bar

The numbers

MetricEveSignos
WeighScore66/10061.4/100
GradeCC
Scorecard rank#212#295
Semaglutide$195/mo (compounded)$199/mo (6-month plan, compounded)
Tirzepatide$195/mo (compounded)$199/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
Eve

Graded #212 · C

Strengths

  • Genuinely women's-health-focused — fills a real gap among gender-neutral GLP-1 competitors
  • Both compounded and brand-name FDA-approved options (Wegovy/Ozempic/Mounjaro) on one platform — rare
  • LegitScript Certified with a verifiable ID
  • Publishes the FDA compounded-medication disclaimer
  • Oral sublingual semaglutide offered alongside injectable

Where it loses points

  • Full states-served list not disclosed publicly
  • 503A pharmacy partner not named, and 503A vs 503B status not specified
  • Named medical director / clinical leadership not disclosed
  • Corporate legal entity not disclosed
  • Governing law / arbitration venue not stated
Signos

Graded #295 · C

Strengths

  • Bundles compounded GLP-1 (semaglutide) with an FDA-cleared CGM and app — glucose-guided weight loss, not just medication
  • Starting at $199/mo on a 6-month program, with the CGM included at no extra cost
  • Free rapid shipping; HSA/FSA eligible
  • Real-time glucose insights and app coaching to help sustain results after GLP-1

Where it loses points

  • Compounded GLP-1s are not FDA-approved finished products
  • Headline price is a 6-month-program rate, not month-to-month
  • Only semaglutide is shown in the program; tirzepatide availability is not confirmed
  • Compounding pharmacy partner and state availability are not published on the landing page

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard